Allakos Management

The company’s lead antibodies are AK001 and AK002 intended for the treatment of severe allergic diseases and diseases characterized by excess activity of mast cells and eosinophils.

Data Table
    AK001 is a therapeutic antibody targeting an inhibitory receptor on mast cells and eosinophils. It engages a key immunological pathway that plays a natural role in the modulation of allergic and inflammatory responses. AK001 engagement of this receptor causes inhibition of mast cells and selective depletion of activated eosinophils. AK001 has demonstrated activity in multiple sophisticated animal models of severe allergic diseases. Its key differentiators include:
  • Engagement of a natural immune mechanism to reduce allergic responses with potential to help restore balance to these immune responses

  • Inhibition of mast cells following exposure to several different stimuli

  • Selective depletion of activated and tissue eosinophils

  • Potential for rapid onset of action based on the ability to target both mast cells and tissue eosinophils
    AK002 is a therapeutic antibody with the ability to induce the killing of mast cells and eosinophils. It has potential for use in the treatment of severe diseases with abnormal proliferation of mast cells, including systemic mastocytosis, a severe, often life-threatening orphan disease.
  • AK002 has demonstrated activity in sophisticated pre-clinical models of mast-cell activity and systemic mastocytosis developed by Allakos in collaboration with experts in the field of mast cell and eosinophil biology
    AK003 is an antibody targeting receptors on effector cells for use in immuno-oncology applications. The program is currently in discovery phase.